Effect of angiotensin-converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function.

Mitral regurgitation (MR) is a common, frequently asymptomatic valvulopathy that can ultimately lead to left ventricular failure. With the objective of forestalling MR progression, a prospective, placebo controlled, double-blind study was conducted. It measured the effectiveness of lisinopril, an angiotensin-converting enzyme inhibitor, in reducing the echocardiographic signs of MR severity over a one-year period. Severe coronary disease was excluded by stress echocardiography. Treatment effectiveness was estimated to be proportional to the reduction in MR fraction and cardiac chamber dimensions, compared with baseline, according to intention-to-treat analysis. A final patient population of 23 asymptomatic adults aged 53.3 +/- 2.4 years (mean +/- SEM), with moderate, organic MR and normal left ventricular function was selected from the echocardiographic database. All baseline patient characteristics were comparable in the two treatment groups, including the MR fraction (55 +/- 3%). Twelve patients received lisinopril (18 +/- 1 mg) and 11 received placebo. After one year of treatment, a statistically significant difference in the MR fraction was observed between the two groups. For the lisinopril group the MR fraction dropped by 6.4 +/- 3.5% and for the placebo group it increased by 3.7 +/- 3.2% versus baseline (P < 0.05). No differences in left atrial or ventricular dimensions were observed. The study drug was stopped in four patients after one patient presented with rapid atrial fibrillation and angina while three patients were intolerant to lisinopril. Only one patient receiving placebo was taken off therapy. In conclusion, treatment with lisinopril indicates some reduction in the severity of chronic moderate MR in asymptomatic patients with normal left ventricular function. This approach appears to be safe, but side effects are not uncommon, warranting regular follow-up.

The effect of prosthesis-patient mismatch on aortic bioprosthetic valve hemodynamic performance and patient clinical status.

BACKGROUND: High pressure gradients occurring through normally functioning prosthetic valves appear to be related to a mismatch between the effective orifice area of the prosthesis and the patient's body surface area. OBJECTIVE: To determine whether prosthesis-patient mismatch affects clinical and hemodynamic status, a group of patients with a bioprosthetic heart valve in the aortic position was prospectively evaluated at 6.2+/-4.4 years after implantation by transthoracic Doppler echocardiography. METHODS: Manufacturer-derived in vitro valve areas were available in 61 patients allowing classification into two subgroups, with or without mismatch, based on a valve area at implantation indexed for body surface area 0.85 cm2/m2 or less, or greater than 0.85 cm2/m2. Clinical and hemodynamic parameters evaluated at follow-up included New York Heart Association (NYHA) class distribution, mean transprosthetic gradient, prosthetic valve area and cardiac index. RESULTS: Prosthesis-patient mismatch was present in 32 of 61 patients (52%). Although NYHA class of the patients was similar in both groups, hemo-dynamic performance of the aortic bioprostheses was worse in patients with mismatch than in patients with no mismatch, as indicated by a higher mean gradient (22+/-9 versus 15+/-8 mm Hg, P=0.002) and a lower cardiac index (3.0+/-0.7 versus 3.4+/-0.7 L/min/m2, P=0.04). The prevalence and severity of intrinsic prosthetic dysfunction were similar in both groups. Despite similar NYHA functional class distribution in both groups, the occurrence of syncope, acute pulmonary edema and angina pectoris was significantly higher in patients with mismatch (50% versus 21%, P=0.017). CONCLUSIONS: Prosthesis-patient mismatch is associated with worse hemodynamic performance and higher prevalence of adverse clinical events. However, mismatch did not promote accelerated hemodynamic or structural deterioration of the bioprosthesis.

Substitution of left ventricular outflow tract diameter with prosthesis size is inadequate for calculation of the aortic prosthetic valve area by the continuity equation.

It remains uncertain whether prosthetic ring size should be used interchangeably with measured left ventricular outflow tract (LVOT) diameter in the continuity equation to estimate the aortic prosthetic valve area by transthoracic Doppler echocardiography. To determine the difference in area caused by this substitution, the area of the prosthetic valve was calculated in 143 patients with aortic bioprostheses by use of the standard continuity equation with the measured LVOT diameter (LVOT method) and then with the bioprosthetic size (size method). Compared with known in vitro prosthetic valve areas, the LVOT method (r = 0.86; standard error of the estimate +/- 0.16 cm2; p < 0.001) was more accurate than the size method (r = 0.74; standard error of the estimate +/- 0.40 cm2; p < 0.001). The prosthetic valve area estimated by the size method overestimated the area estimated by the LVOT method by an average of 15% +/- 23% (p < 0.001). This difference in area between the two methods has increased with the interval since implantation of the bioprosthesis (p = 0.01). It is concluded that prosthetic size should not be used instead of LVOT diameter during calculation of aortic prosthetic valve area. This restriction is particularly important in patients with older bioprosthesis.

A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure.

Cardiac sympathetic neuronal degeneration accompanies mechanical overload heart failure. We hypothesized that sympathetic nerve and myocyte failure share a common etiology and that 123I-metaiodobenzylguanidine (MIBG) might provide a precise method of detecting failure in chronic mechanical overload. Our aim was to develop a method for the dynamic analysis of 123I-MIBG scintigrams which could yield a quantitative index of myocardial sympathetic neuronal function in this condition. We performed serial 123I-MIBG scintigraphy in 33 volunteers, 10 orthotopic cardiac transplant recipients and 26 patients with chronic mechanical overload of the left ventricle. We constructed a compartmental model in which total heart activity represents the sum of cardiac sympathetic vesicular and cytosolic pools. Patients with antecedent mechanical overload heart failure or myocardial dysfunction had accelerated myocardial egress of tracer that we ascribed to a specific impairment in vesicular storage rather than to a more rapid turnover of an intact vesicular pool.

Use of Valsalva maneuver to unmask left ventricular diastolic function abnormalities by Doppler echocardiography in patients with coronary artery disease or systemic hypertension.

It has been suggested that changes in left atrial pressure may mask or mimic left ventricular diastolic function abnormalities detected by Doppler echocardiography. The effect of the Valsalva maneuver on the transmitral flow velocity profile was therefore studied in 28 patients without evidence of coronary artery disease (group 1, mean age +/- standard deviation 50 +/- 8 years) and in 94 patients with evidence of coronary artery disease or systemic hypertension (group 2, mean age 54 +/- 10 years). At baseline, group 2 patients had higher peak late diastolic filling velocity (A), lower peak early (E) to late diastolic filling velocity (E/A) ratio and longer isovolumic relaxation time than group 1, whereas heart rate, E velocity and E deceleration time were similar in both groups. During Valsalva, both groups had similar increases in heart rate and similar decreases in E velocity but E/A ratio decreased significantly only in group 2 because of a lesser decrease in A velocity. The E/A ratio was greater than or equal to 1.0 both before and during Valsalva in all but 1 patient in group 1, whereas in group 2, 32 patients had E/A greater than or equal to 1.0 at rest and during Valsalva, 33 patients had E/A greater than or equal to 1.0 at rest but less than 1.0 both at rest and during Valsalva. Using group 1 as controls, prevalence, specificity and positive predictive value of E/A less than 1.0 in group 2 were 31, 100 and 100% at rest and 66, 96 and 98% during Valsalva.(ABSTRACT TRUNCATED AT 250 WORDS)

Validation and applications of indexed aortic prosthetic valve areas calculated by Doppler echocardiography.

Doppler echocardiographic evaluation of aortic valve prostheses is based on the use of variables heretofore validated mostly for native valves. Accordingly, this study examined the validity and relative usefulness of the Doppler valve gradient and area measurements in 31 patients (mean age 69 +/- 10 years) 20 +/- 4 months after implantation of a given type of aortic bioprosthesis ranging in size from 19 to 29 mm. Valve area data obtained with both the standard and simplified continuity equations were compared with known in vitro prosthetic valve area measurements and an excellent correlation was obtained between the standard and simplified continuity equations (r = 0.98, SEE +/- 0.07 cm2, p less than 0.0005) and between in vivo and known in vitro prosthetic valve areas (r = 0.86, SEE +/- 0.16 cm2, p less than 0.0005). Peak gradient ranged from 10.8 to 75.0 mm Hg (mean 35 +/- 16) and mean gradient from 7.6 to 43.7 mm Hg (mean 20.5 +/- 9.5). The correlations between prosthetic valve gradient and in vivo area were r = -0.53, SEE +/- 14 mm Hg and r = -0.49, SEE +/- 8.63 mm Hg for peak and mean gradient, respectively. These relations were improved by indexing valve area by body surface area. The best correlations were obtained between indexed valve area and a quadratic function of the gradient (r = -0.72, SEE +/- 11.72 mm Hg and r = -0.70, SEE +/- 7.28 mm Hg for peak and mean gradient, respectively), reflecting a curvilinear relation.(ABSTRACT TRUNCATED AT 250 WORDS)

Validation and applications of mitral prosthetic valvular areas calculated by Doppler echocardiography.

Doppler echocardiography is used in the noninvasive evaluation of mitral valve prostheses using parameters heretofore validated primarily for native valves. Accordingly, this study was designed to examine the validity and relative usefulness of valve gradient and area measurements in a group of 26 patients (17 women, 9 men, mean age 62 +/- 8 years), 19 +/- 4 months after implantation of different sizes (25 to 31 mm) of a given type of bioprosthesis. Areas obtained with both the continuity equation, using stroke volume measured in the left ventricular outflow tract, and the pressure half-time method are compared to known prosthetic areas derived from an in vitro hydraulic model. Areas calculated by the continuity equation correlate well with in vitro areas (r = 0.82, standard error of the y estimate = 0.1 cm2, p less than 0.001), and are within the range of predicted in vitro values in 92% of cases. Areas derived by the pressure half-time method do not correlate with in vitro areas (r = 0.15, p greater than 0.3) or continuity equation areas (r = 0.23, p greater than 0.2), and are above the range of predicted values in 69% of cases. Correlations are also found between continuity equation areas and the peak and mean valvular gradients (r = 0.59, p less than 0.005 and r = -0.63, p less than 0.0005, respectively). Taking the effect of cardiac output on gradients into account results in projected relations between indexed prosthetic areas and the pressure gradients at rest and during exercise.(ABSTRACT TRUNCATED AT 250 WORDS)